Daily Cosmetic Research Analysis

BACKGROUND: Radiofrequency microneedling (RFMN) utilizes RF energy delivered via needles to the dermis to enhance texture, reduce laxity, and improve dyschromia. However, evidence has been fragmented by indication/device heterogeneity. We evaluated clinical effectiveness, safety, and patient-reported outcomes (PROs) of RFMN across dermatological conditions. METHODS: Searches of PubMed, Google Scholar, and Semantic Scholar (January 2015-July 2025) (PROSPERO registration: CRD420251089393) were conducted, and English-language RCTs, cohort studies, case series, and reports of RFMN across skin indications were included (non-human studies excluded). A modified Critical Appraisal Skills Programme (CASP) checklist was used for quality analysis. Findings were narratively synthesized. RESULTS: Forty-one studies met the criteria (15 RCTs, 19 prospective non-randomized studies, 5 prospective cohorts, 2 case series) spanning diverse geographies and Fitzpatrick skin types. For atrophic acne scars, RFMN consistently reduced scar scores and demonstrated efficacy comparable to fractional lasers. For skin laxity/photoaging, RFMN improved wrinkle scales, dermal density, and submental volume, (histologically evidenced). Additional benefits were noted for rosacea, melasma, and striae, though effect sizes varied. In primary axillary hyperhidrosis, botulinum toxin A outperformed RFMN for symptom reduction/comfort. Safety was favorable; erythema, edema, and transient pain predominated; post-inflammatory hyperpigmentation was infrequent and self-limited. PROs indicated high satisfaction and minimal downtime. Reporting of technical parameters, especially temperature, pulse width, and cooling, was inconsistent. CONCLUSIONS: RFMN is safe, well-tolerated, with credible efficacy across multiple indications and skin types, and an attractive recovery profile. Standardized outcomes, longer follow-up periods, and rigorous reporting of device settings are necessary to refine protocols and facilitate head-to-head device comparisons. LEVEL OF EVIDENCE III: This journal requires that authors assign a level of evidence to each article. For a full description of these evidence-based medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .

INTRODUCTION: Reduction mammoplasty (RM) ranks as one of the most prevalent aesthetic surgical interventions globally. Since breasts are widely associated with femininity and sexual identity, many patients pursue RM with the expectation of enhancing their sexual life. OBJECTIVES: This study aims to examine the impact of RM on postoperative sexual function. METHODS: A comprehensive search was performed in electronic databases to identify articles published up to April 15, 2025. Following the removal of duplicates, 441 articles were identified to be in line with the objectives of this study. A meta-analysis was used to derive weighted pooled estimates of sexual function after RM using a random-effects model. RESULTS: After the use of eligibility criteria and exclusion of irrelevant studies, 13 articles comprising 676 participants were included in the final analysis. Nine of the included studies demonstrated a significant improvement in sexual function following RM, while 4 reported no significant changes in that regard. A meta-analysis of 8 studies that have been utilizing standardized instruments demonstrated that RM was associated with 13.27% increase in the mean score of sexual function. CONCLUSION: The findings of this systematic review revealed that female sexual function improves following RM. However, given the outlined limitations, further rigorous research is needed to confirm these results.

OBJECTIVE: To describe the clinical outcome of intravitreal cidofovir injection for palliative management of refractory end-stage glaucoma and vision loss in silicone oil-filled eyes following retinal reattachment surgery in dogs. PROCEDURES: Medical records of dogs that underwent a single intravitreal cidofovir injection for pharmacologic ciliary body ablation were retrospectively reviewed. Data collected included clinical history, intraocular pressure (IOP), post-injection ocular comfort, complications, and follow-up duration. RESULTS: Four dogs (four eyes) were included. All treated eyes demonstrated a marked reduction in IOP at the first post-injection recheck (14-28 days after injection; post-injection IOP range: 3-7 mmHg). Adequate pain control was achieved in all dogs throughout the follow-up period (median follow-up: 306.5 days; range: 40-369 days). Progressive phthisis bulbi developed in one case at long-term follow-up, while the remaining eyes maintained acceptable globe integrity and cosmetic appearance. Moderate to severe post-injection ocular discharge, conjunctival hyperemia, and aqueous flare were observed in all cases and were manageable with routine topical therapy. All owners reported satisfaction with post-injection comfort and appearance. CONCLUSIONS: A single intravitreal cidofovir injection may represent a feasible palliative option for controlling intraocular pressure and ocular pain in silicone oil-filled eyes with refractory glaucoma when enucleation is declined. Further studies are needed to better characterize long-term safety and outcomes in this clinical setting.